THERAPY DOSSIER · th-be989d559433

Osthole, a natural coumarin derivative

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23548945 ↗2013Reported benefit

Osthole ameliorates renal ischemia-reperfusion injury by inhibiting inflammatory response.

RatIschaemia-reperfusionRenalSprague-DawleyMaleIntraperitoneal40 mg/kg30 minutes before induction of ischaemia-reperfusion

Model: Clamping of the left renal artery for 45 minutes followed by 12 hours of reperfusion and contralateral nephrectomy

Osthole pre-treatment improved renal function and histology and reduced neutrophil and monocyte/macrophage infiltration and inflammatory mediator expression after renal ischaemia-reperfusion.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…